News

Business Wire2y
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents - Business Wire
Merck’s ongoing pneumococcal vaccine development program is designed to provide tailored options to address the specific needs of different populations, including infants and children, ...
Business Wire8mon
Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease - Business Wire
Merck’s ongoing pneumococcal vaccine development program is designed to provide options that address the specific needs of different populations, including infants and children, ...
Healio1y
FDA approves Merck’s pneumococcal vaccine for adults - Healio
The vaccine, called Capvaxive, covers serotypes of pneumococcus bacteria that are responsible for around 84% of invasive pneumococcal disease occurring in adults aged 50 years or older and 85% of ...
Hosted on MSN1y
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults - MSN
Monday, the FDA approved Merck & Co Inc’s (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.
FierceBiotech1y
Merck compares pneumococcal vaccine to 1983 warhorse - Fierce Biotech
With an approval, Merck has a chance to grab a larger share of the pneumococcal vaccine market. In 2023, the company scored $665 million in sales of its 15-valent pneumococcal shot Vaxneuvance ...
STAT1y
New Merck pneumococcal vaccine Capvaxive wins FDA approval - STAT
T he Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older.. The vaccine, which will be sold under the name Capvaxive, is designed to protect ...
Pharm Exec1y
Merck's 21-Valent Pneumococcal Conjugate Vaccine Granted FDA Priority Review - PharmExec
The FDA has granted priority review to Merck’s Biologics License Application (BLA) for V116, a novel 21-valent pneumococcal conjugate vaccine developed as a single dose for the prevention of invasive ...
FiercePharma1y
FDA approves first pneumococcal vaccine designed for adults - Fierce Pharma
Merck now has a chance to grab a larger share of the pneumococcal vaccine market. In 2023, the company scored $665 million in sales of its 15-valent pneumococcal shot Vaxneuvance (formerly V114 ...
NBC New York1y
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections - NBC New York
Merck's pneumococcal vaccine protects against eight strains of the bacteria that are not included in any other approved shot for the disease.
NBC Los Angeles1y
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections - NBC Los Angeles
Merck’s shot protects against 21 strains of that bacteria to prevent a severe form of pneumococcal disease and a lung infection called pneumonia.
Benzinga.com1y
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults - Merck & Co (NYSE:MRK) - Benzinga
Monday, the FDA approved Merck & Co Inc’s (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.